Comparison of Anti HIV Drugs Used Alone or in Combination With Cytosine Arabinoside to Treat Progressive Multifocal Leukoencephalopathy (PML) in HIV-Infected Patients - Related Studies

Comparison of Anti HIV Drugs Used Alone or in Combination With Cytosine Arabinoside to Treat Progressive Multifocal Leukoencephalopathy (PML) in HIV-Infected Patients

This study has been completed.

Study NCT00001048. Last updated on July 29, 2008. Information provided by National Institute of Allergy and Infectious Diseases (NIAID)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		HIV Infections

2	Additional conditions recognized in this trial
		Acquired Immunodeficiency Syndrome
		Infection
		Leukoencephalopathy, Progressive Multifocal

3	More general conditions related to this trial
		Central Nervous System Diseases
		Central Nervous System Infections
		Central Nervous System Viral Diseases
		Demyelinating Diseases
		DNA Virus Infections
		Encephalitis
		Encephalitis, Viral
		Immune System Diseases
		Immunologic Deficiency Syndromes
		Lentivirus Infections
		Nervous System Diseases
		Polyomavirus Infections
		Retroviridae Infections
		RNA Virus Infections
		Sexually Transmitted Diseases
		Sexually Transmitted Diseases, Viral
		Slow Virus Diseases
		Virus Diseases

4	Interventions listed in this trial
		Filgrastim
		Cytarabine
		Zidovudine
		Zalcitabine
		Didanosine

5	More general drug interventions related to this trial
		Anti-HIV Agents
		Anti-Infective Agents
		Anti-Retroviral Agents
		Antimetabolites
		Antimetabolites, Antineoplastic
		Antineoplastic Agents
		Antiviral Agents
		Enzyme Inhibitors
		Immunologic Factors
		Immunosuppressive Agents
		Molecular Mechanisms of Pharmacological Action
		Nucleic Acid Synthesis Inhibitors
		Pharmacologic Actions
		Physiological Effects of Drugs
		Reverse Transcriptase Inhibitors
		Therapeutic Uses

6	Sponsors listed in this trial
		National Institute of Allergy and Infectious Diseases (NIAID)
		Bristol-Myers Squibb
		Upjohn